Download Files:
Navitoclax-piperazine
$190 – $2,900
Products Details
Product Description
– Navitoclax-piperazine (ABT-263-piperazine) is a B-cell lymphoma extra large (BCL-XL) inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604)[1].
Web ID
– HY-44432
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C47H56ClF3N6O5S3
References
– [1]Sajid Khan, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med 25, 1938–1947 (2019).
CAS Number
– 2143096-93-7
Molecular Weight
– 973.63
Compound Purity
– 99.21
SMILES
– O=C(NS(=O)(C1=CC=C(N[C@@H](CSC2=CC=CC=C2)CCN3CCNCC3)C(S(=O)(C(F)(F)F)=O)=C1)=O)C4=CC=C(N5CCN(CC6=C(C7=CC=C(Cl)C=C7)CCC(C)(C)C6)CC5)C=C4
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 125 mg/mL (ultrasonic)
Target
– Bcl-2 Family;Ligands for Target Protein for PROTAC
Isoform
– Bcl-xL
Pathway
– Apoptosis;PROTAC
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
